Oliver J. Stoetzer
Franz Schrank Str. 2
Munich, BY 80638, Germany
Munich, BY 80638, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).
Journal: ESMO open
Published: June 18, 2025
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.
Journal: BMC medicine
Published: February 14, 2024
Targeted Sequencing of Human Satellite 2 Repeat Sequences in Plasma cfDNA Reveals Potential Breast Cancer Biomarkers.
Journal: Diagnostics (Basel, Switzerland)
Published: January 22, 2024
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Journal: International journal of cancer
Published: August 03, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 14, 2023
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 18, 2022
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Journal: Breast cancer research : BCR
Published: October 05, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: May 19, 2022
Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
Journal: Breast care (Basel, Switzerland)
Published: July 26, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Journal: The Lancet. Oncology
Published: March 25, 2021
Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: January 05, 2021
Last Updated: 09/26/2026